EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial

Usman Baber iD, Davide Cao iD, Timothy Collier iD, Samantha Sartori iD, George Dangas, Dominick J Angiolillo, Birgit Vogel iD, Vijay Kunadian iD, Carlo Briguori iD, David J Cohen iD, Dariusz Dudek, C Michael Gibson und 17 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae080 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Usman Baber und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Hauptthemen laut MEDLINE: Ticagrelor, Percutaneous Coronary Intervention, Aspirin, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Icahn School of Medicine at Mount Sinai, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In standard time-to-first event analysis, early aspirin discontinuation followed by ticagrelor monotherapy has been shown to reduce bleeding without increasing ischaemic complications compared with ticagrelor plus aspirin after percutaneous coronary intervention (PCI). We evaluated whether these treatment effects are preserved when recurrent events are considered. Methods and results In this TWILIGHT trial post-hoc analysis, we assessed the effects of ticagrelor monotherapy on the total number of events that occurred over the 12-month follow-up among 7119 high-risk patients randomized to aspirin or placebo in addition to ticagrelor at 3 months post-PCI if event-free and adherent to treatment. There were 391 patients with at least one Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding (primary endpoint). Of those, 28 (7.2%) had a recurrent event. The total number of BARC 2, 3, or 5 bleeding events was 148 in the ticagrelor monotherapy arm compared with 278 with ticagrelor plus aspirin arm (P < 0.001). Among 272 patients with at least one key secondary ischaemic endpoint (all-cause death, myocardial infarction, or stroke), 37 (13.6%) sustained a recurrent event. Total ischaemic events were similar (155 vs. 159) in the two groups.

Conclusion

Among selected high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy followed by ticagrelor with or without aspirin, recurrent bleeding was less common than recurrent ischaemic events over 12 months. Analysis of total events indicates that ticagrelor monotherapy continues to be more effective than ticagrelor plus aspirin in reducing bleeding without a signal of ischaemic harm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorPercutaneous Coronary InterventionAspirinPlatelet Aggregation InhibitorsHemorrhagePurinergic P2Y Receptor AntagonistsHumansFemaleMaleAgedMiddle AgedRecurrenceTime FactorsTreatment OutcomeRisk FactorsDrug Therapy, CombinationRisk AssessmentDouble-Blind MethodDual Anti-Platelet Therapy

Stichwörter der Autor:innen

AspirinBleedingPCIRecurrent eventsThrombosisTicagrelor monotherapy

Substanzen

TicagrelorAspirinPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, NY 10029, USA.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI 20090, Italy.
  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL 32209, USA.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.

ORCID-Profile: Usman Baber, Davide Cao, Timothy Collier, Samantha Sartori, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J Cohen, Robert Gil, Kurt Huber, Javier Escaned, Richard Shlofmitz, Roxana Mehran

Förderung

  • Icahn School of Medicine at Mount Sinai
  • AstraZeneca

Zitieren

APA

Baber, U., Cao, D., Collier, T., Sartori, S., Dangas, G., Angiolillo, D. J., Vogel, B., Kunadian, V., Briguori, C., Cohen, D. J., Dudek, D., Gibson, C. M., Gil, R., Huber, K., Kaul, U., Kornowski, R., Krucoff, M. W., Mehta, S., Moliterno, D. J., …, & Mehran, R. (2025). Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae080

Vancouver

Baber U, Cao D, Collier T, Sartori S, Dangas G, Angiolillo DJ, et al. Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae080

BibTeX
@article{Baber2025,
  author = {Baber, Usman and Cao, Davide and Collier, Timothy and Sartori, Samantha and Dangas, George and Angiolillo, Dominick J and Vogel, Birgit and Kunadian, Vijay and Briguori, Carlo and Cohen, David J and Dudek, Dariusz and Gibson, C Michael and Gil, Robert and Huber, Kurt and Kaul, Upendra and Kornowski, Ran and Krucoff, Mitchell W and Mehta, Shamir and Moliterno, David J and Ohman, E Magnus and Escaned, Javier and Sardella, Gennaro and Sharma, Samin K and Shlofmitz, Richard and Weisz, Giora and Witzenbichler, Bernhard and Steg, P Gabriel and Pocock, Stuart and Mehran, Roxana},
  title = {Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae080}
}
Kostenlos starten →